Breaking News
Investing Pro 0
Last Call for Cyber Monday! Save Now on Claim 60% OFF
Close

Neurocrine Biosciences Inc (NBIX)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Neurocrine's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
117.12 +0.53    +0.45%
01/12 - Closed. Currency in USD ( Disclaimer )
After Hours
118.00
+0.88
+0.75%
01/12
  • Volume: 852,091
  • Bid/Ask: 117.34 / 119.05
  • Day's Range: 115.82 - 117.79
Type:  Equity
Market:  United States
Neurocrine 117.12 +0.53 +0.45%

Neurocrine Biosciences Inc Company Profile

 
Read the Neurocrine company profile to learn more about the business and the management team. View employee data, company address and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

1350

Equity Type

ORD

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company’s portfolio includes treatments for tardive dyskinesia, Parkinson’s disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its products include INGREZZA and DYSVAL, for the treatment of tardive dyskinesia. The company’s commercial products include ONGENTYS, used as an adjunctive therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson’s disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women, as well as ALKINDI SPRINKLE, for the treatment of pediatric adrenal insufficiency. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company’s products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-1117568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL – Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; Sentia Medical Sciences Inc.; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

Contact Information

Address 12780 El Camino Real
San Diego, 92130
United States
Phone 858 617 7600
Fax 858 617 7602

Top Executives

Name Age Since Title
Kevin C. Gorman 63 2006 CEO & Director
Richard F. Pops 59 1998 Independent Director
William H. Rastetter 73 2010 Independent Chairman of the Board
Stephen A. Sherwin 73 1999 Independent Director
Gary A. Lyons 71 1993 Independent Director
Johanna Mercier 52 2021 Independent Director
Leslie V. Norwalk 57 2019 Independent Director
George J. Morrow 70 2015 Independent Director
Shalini Sharp 47 2020 Independent Director
Christine Ann Poon 71 2023 Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

NBIX Comments

Write your thoughts about Neurocrine Biosciences Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Paul Liew
Paul Liew Aug 29, 2020 12:33
Saved. See Saved Items.
This comment has already been saved in your Saved Items
2020.08.26 @ $116
Liew ST
Liew ST Aug 29, 2020 12:33
Saved. See Saved Items.
This comment has already been saved in your Saved Items
24/7. 2021Mar. $88. BOA Tgt $128
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email